The aim of this multicenter non-controlled study is to develop a multivariable prediction model of pain/disability improvements in patients with meniscal tears, after a physical therapy treatment based on therapeutic exercise and education.

Start Date01 May 2024

Sponsor / Collaborator

Hospital Universitario Principe De Asturias

[+4]

NCT05913050

/ RecruitingNot ApplicableIIT

Predicting ROtator Cuff Tears Outcomes After Physical Therapy Treatment (the PROTO Study): a Multivariable Prediction Model Development Study

The aim of this multicenter non-controlled study is to develop a multivariable prediction model of pain/disability improvements in patients with full-thickness rotator cuff tears, after a physical therapy treatment based on therapeutic exercise and education.

Start Date01 May 2024

Sponsor / Collaborator

Hospital Universitario Principe De Asturias

[+4]

NCT05909930

/ RecruitingNot ApplicableIIT

Effectiveness of TheRApeutic ExercIse aNd EDucation on Patients With Massive Rotator Cuff Tears (the TRAINED Study): a Multicenter Non-controlled Trial

The aim of this multicenter non-controlled study will be to evaluate the effectiveness of a physical therapy treatment based on resistance exercise and education for patients with massive rotator cuff tears.

Start Date01 May 2024

Sponsor / Collaborator

Hospital Universitario Principe De Asturias

[+4]

100 Clinical Results associated with Hospital Universitario de Fuenlabrada

0 Patents (Medical) associated with Hospital Universitario de Fuenlabrada

1,447

Literatures (Medical) associated with Hospital Universitario de Fuenlabrada

01 May 2025·JHEP Reports

Evolving epidemiology of HCC in Spain

Article

Author: Hernáez-Alsina, Tánia ; Sala, Margarita ; Peñas, Irene ; Perelló, Christie ; Rodríguez-Lope, Carlos ; Cortés-García, Luís ; Fernández-López, Alexia María ; Ferrer, María Teresa ; Díaz-Bethencourt, Dácil ; Vallejo-Senra, Nicolau ; Rodríguez, Manuel ; Chiminazzo, Valentina ; Llamoza-Torres, Camilo Julio ; Macías-Rodríguez, Manuel Alberto ; Roget, Mercè ; Matilla, Ana María ; Delgado, Manuel ; Vergara, Mercedes ; Hernández-Guerra, Manuel ; Aracil, Carles ; Varela, María ; Díaz-González, Álvaro ; Fernández-Bermejo, Miguel ; Morillas, María Julia ; Valer López-Fando, María Paz ; Bustamante, Javier ; Gómez-Rubio, Mariano ; Cuyás, Berta ; Molina, Esther ; Guiberteau, Ana ; Giraldez, Álvaro ; Lázaro, María ; Campos, Marta ; Guerrero, Marta ; Montoliu, Silvia ; González-Santiago, Jesús Manuel ; Reig, María ; Olmo, Javier Fuentes ; Cachero, Alba ; Gacho, Pilar Conde ; Fernández-Marcos, Cristina ; Lué, Alberto ; Urquijo Ponce, Juan José ; Barrio, Mónica Llorente ; Serra, Isabel ; Castro, Raisa Quiñones ; Montero, José Luís ; Coll, Susana ; Unceta, Paloma Rendón ; Serra, Hernán Andreu ; Gutiérrez-García, María Luisa ; Iñarrairaegui, Mercedes ; Sánchez, Araceli García ; Ramos, Irina Calvo ; Pascual, Sonia ; Olmedo, Susana Rebolledo ; Vázquez-Rodríguez, Sergio ; Delgado, Carolina ; Guerrero, Antonio ; Mínguez, Beatriz ; Sogbe, Miguel ; Rifà, Raimon ; Lledó, José Luis ; Rota Roca, Maria Rosa ; Clos, Ariadna ; Romero-Gutiérrez, Marta ; Segarra, José Xavier ; Pacheco Del Río, Gemma ; Rodríguez-González, María Milagros ; Bermúdez-Ramos, María

Background & AimsThe epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain.MethodsThis multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014.ResultsOf the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments.ConclusionsAlcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management.Impact and implicationsOur study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs.

23 Apr 2025·European Heart Journal: Acute Cardiovascular Care

Prognostic impact of obesity in acute aortic syndrome patients

Author: Perez Villacastin, J ; Da Rosa Beltrao, S M ; Carrero, A ; Vilacosta, I ; Munoz Sahagun, P ; Hernandez Mateo, M ; Ramos Gonzalez-Cristobal, I ; Carnero Alcazar, M ; Navarro Garcia, M L ; Cobiella, J ; Ferrera Duran, C F D ; Martinez, I ; Maroto-Castellanos, L ; Gonzalez Del Castillo, J ; Alvarez, E

AbstractIntroductionObesity is a global health problem with a well-known prognostic impact on cardiovascular pathologies. The influence of obesity and body mass index (BMI) on the prognosis of patients with acute aortic syndrome (AAS) is not clearly defined. Our aim is to evaluate whether overweight or obesity are associated with worse AAS prognosis.MethodsAll patients with AAS attended in a tertiary centre from April-2019 to 2024 were prospectively and consecutively collected. Height and weight at admission were recorded and patients were classified according to BMI into normal-weight (18.5 ≤BMI<25), overweight (25 ≤BMI<30) and obese (BMI≥30). Clinical, analytical, imaging and prognostic variables were analysed. Multivariate logistic regression analysis was performed to identify prognostic factors including age, sex, history of atrial fibrillation, and cardiovascular risk factors (hypertension, diabetes, obesity, peripheral artery disease, chronic kidney disease).ResultsA total of 132 patients with AAS were included (table). Overweight or obese patients were more prevalent and significantly younger (p=0.011): normal weight (age 70±18.6 years), overweight (age 64±13.4 years) and obese (age 67±11, 4 years).No differences were found in the AAS type diagnosed between groups(p=0.524): type A AAS was the most prevalent (73% normal-weight, 67% overweight and 75% obese) and aortic dissection the most common subtype (76% normal-weight, 82% overweight and 85% obese).Clinical presentation was similar between the three groups of patients (Table). Although the differences were not statistically significant, type A AAS patients with obesity had a higher percentage of complications on admission (Table). Regarding in-hospital evolution, obese type A AAS patients had higher overall 30-day mortality and higher postoperative mortality (Figure). In a multivariate analysis, obesity showed a significant independent association with higher 30-day mortality (OR 6.86, 95%CI (1.30-36.2), p=0.023).ConclusionIn this AAS patient population, two thirds had overweight or obesity, according to BMI. Patients with obesity showed worse prognosis and higher mortality compared to overweight patients.Obesity was independently associated with a higher mortality.Mortality in AAS according to weight

01 Apr 2025·ESMO Open

LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional study

Article

Author: Cardeña-Gutiérrez, A ; López, R ; Provencio-Pulla, M ; Romão, R ; Aparisi, F ; Arango, N ; Azkona-Uribelarrea, E ; Collazo-Lorduy, A ; Sereno, M ; Blasco-Cordellat, A ; Peralta, D ; Ospina-Serrano, A V ; Antoñanzas, M ; Triana, I ; Losada, B ; Avendaño, A C ; Ramos, P ; Moran, T ; Blanco, M ; Casas-Cornejo, R ; Olivares-Hernández, A ; Valdivia, A ; Dómine, M ; Calvo, V ; Cruz, P ; Suay-Montagud, G ; Cordeiro, P ; Carcereny, E ; Guillen-Sentís, P ; Ortega-Gallastegi, B

BACKGROUNDPatients with lung cancer may suffer from sexual dysfunction (SD) related to oncological treatment. This is an under-recognized condition among clinicians. The aim of this study was to describe the prevalence of SD in a multicenter cohort of patients.PATIENTS AND METHODSThis multicenter, cross-sectional, observational study was conducted between July 2023 and February 2024. Sexual function was assessed by patient-reported outcome (PRO) system using sex-specific questionnaire. Descriptive analysis and evaluation of differences between categorical variables were carried out. Associations between clinical characteristics and SD were assessed by logistic regression.RESULTSFour hundred and forty-eight patients from 24 hospitals in Spain, Colombia, Argentina, and Portugal were included. Of these, 277 (61.83%) were male and 365 (81.48%) had metastatic disease. Two hundred and eighty-four patients (63.39%) reported the onset of SD following the initiation of oncological treatment. Males and females reported a high frequency of severe impairment of sexual response phases, which was twice as high in females (P= 0.001). Female sex was a factor for severe impairment of desire, arousal, and orgasm [odds ratio (OR) 3.72, 95% confidence interval (CI) 2.48-5.60, P= 0.001] and decreased sexual activity (OR 1.98, 95% CI:1.17-3.19, P = 0.01), in addition to age over 65 years (OR 3.86, 95% CI 1.01-15.25, P= 0.004) and high educational level (OR 0.29, 95% CI 0.09-0.94, P= 0.0040). Patients from Portugal and Latin America were more likely to report dissatisfaction with sexual activity (OR 3.75, 95% CI 1.06-13.22, P= 0.0039). Female sex (OR 3.53, 95% CI 1.88-6.6, P 0.001), smoking history (OR 1.77, 95% CI 1.01-4.01, P= 0.04), and obesity (OR 1.70 95% CI 1.01-3.16, P= 0.05) were associated with global sexual dissatisfaction.CONCLUSIONSOur patients with lung cancer had a high prevalence of SD after initiation of oncological treatment. There was remarkable sex disparity in the frequency and severity of this disorder as well as an important influence of sociocultural factors in the clinical presentation.

100 Deals associated with Hospital Universitario de Fuenlabrada

100 Translational Medicine associated with Hospital Universitario de Fuenlabrada

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 10 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hospital Universitario de Fuenlabrada

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 10 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing